244.40
0.41 (0.17%)
| Previous Close | 243.99 |
| Open | 242.70 |
| Volume | 41,166 |
| Avg. Volume (3M) | 768,953 |
| Market Cap | 31,522,955,264 |
| Price / Sales | 14.77 |
| Price / Book | 972.68 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | -15.86% |
| Operating Margin (TTM) | -15.35% |
| Diluted EPS (TTM) | -2.61 |
| Quarterly Revenue Growth (YOY) | -33.30% |
| Total Debt/Equity (MRQ) | 8,426.14% |
| Current Ratio (MRQ) | 2.75 |
| Operating Cash Flow (TTM) | 56.55 M |
| Levered Free Cash Flow (TTM) | 309.57 M |
| Return on Assets (TTM) | -2.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.43% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 400.00 (HC Wainwright & Co., 63.67%) | Buy |
| Median | 312.00 (27.66%) | |
| Low | 220.00 (Cantor Fitzgerald, -9.98%) | Hold |
| Average | 320.17 (31.00%) | |
| Total | 11 Buy, 1 Hold | |
| Avg. Price @ Call | 270.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Nov 2024 | 400.00 (63.67%) | Buy | 232.27 |
| 04 Nov 2024 | 400.00 (63.67%) | Buy | 269.95 | |
| Piper Sandler | 18 Nov 2024 | 296.00 (21.11%) | Buy | 232.27 |
| Barclays | 01 Nov 2024 | 329.00 (34.62%) | Buy | 273.91 |
| Canaccord Genuity | 01 Nov 2024 | 384.00 (57.12%) | Buy | 273.91 |
| Chardan Capital | 01 Nov 2024 | 300.00 (22.75%) | Buy | 273.91 |
| 11 Oct 2024 | 300.00 (22.75%) | Buy | 284.32 | |
| Needham | 01 Nov 2024 | 320.00 (30.93%) | Buy | 273.91 |
| 10 Oct 2024 | 320.00 (30.93%) | Buy | 278.62 | |
| RBC Capital | 01 Nov 2024 | 300.00 (22.75%) | Buy | 273.91 |
| 10 Oct 2024 | 300.00 (22.75%) | Buy | 278.62 | |
| Raymond James | 01 Nov 2024 | 298.00 (21.93%) | Buy | 273.91 |
| Scotiabank | 01 Nov 2024 | 310.00 (26.84%) | Buy | 273.91 |
| 16 Oct 2024 | 305.00 (24.80%) | Buy | 300.55 | |
| TD Cowen | 21 Oct 2024 | 371.00 (51.80%) | Buy | 292.01 |
| B of A Securities | 14 Oct 2024 | 314.00 (28.48%) | Buy | 283.32 |
| Cantor Fitzgerald | 11 Oct 2024 | 220.00 (-9.98%) | Hold | 284.32 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GARG PUSHKAL | - | 245.26 | -1,752 | -429,696 |
| Aggregate Net Quantity | -1,752 | |||
| Aggregate Net Value ($) | -429,696 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 245.26 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GARG PUSHKAL | Officer | 12 Dec 2024 | Automatic sell (-) | 1,752 | 245.26 | 429,696 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |